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S u m m a r y 
O B J E C T I V E No satisfactory treatment for adrenocort ical 
c a r c i n o m a ( A C C ) is avai lable . We investigated the effi-
c a c y and toxicity of suramin in the treatment of metastatic 
A C C s i n c e suramin h a s been recently reported to be 
active a s a s ingle agent therapy for patients with A C C 
and prostatic c a r c i n o m a . 
D E S I G N We col lected data on 9 patients with metastatic 
A C C treated with suramin in four centres in G e r m a n y 
between 1987 and 1992. 
PAT IENTS Nine patients (5 women, 4 men; age range 
32 -67 y e a r s ) w e r e included. B iochemica l ev idence of 
steroid e x c e s s w a s found in 6/9, in three leading to 
cl inical symptoms (hypertension, hyperglycaemia, hirsut-
ism, gynaecomast ia ) . 
M E A S U R E M E N T S Tumour r e s p o n s e s were a s s e s s e d by 
radiological and b iochemical evaluation. Other investiga-
tions included regular measurements of blood cel l 
counts , coagulat ion, hepatic and renal function para -
meters , and s e r u m suramin concentrat ions. 
R E S U L T S The patients rece ived cumulat ive d o s e s 
ranging from 8-2 to 30*2 g suramin over per iods of 1 -15 
months. 3/9 ach ieved a partial r esponse , 2/9 d i s e a s e 
stabilization and 4/9 exper ienced progress ive d i s e a s e . 
Tumour r e s p o n s e s were transient. Suramin treatment 
w a s without direct influence on steroid e x c e s s . S e r i o u s 
side-effects included coagulopathy (6/9), thrombocyto-
penia (6/9), polyneuropathy (2/9) and al lergic skin reac -
tions (4/9); the death of two patients w a s possibly related 
to suramin therapy. Both toxicity and tumour r e s p o n s e 
were strongly assoc i a ted with s e r u m level or cumulat ive 
dose of suramin . 
Correspondence: Professor Dr. B. Allolio, Medizinische 
Universitätsklinik, Josef-Schneider-Str. 2, D-97080 Würzburg, 
Germany. 
C O N C L U S I O N S (1) S u r a m i n is of antineoplastic efficacy 
in the treatment of metastat ic adrenocort ical carc inoma. 
(2) The cl inical u s e of s u r a m i n i s limited by a narrow 
therapeutic window with the risk of ser ious and possibly 
lethal toxicity at o n e ext reme, and loss of efficacy at the 
other. Strict monitoring of s u r a m i n s e r u m levels is 
mandatory a iming at l eve ls between 200 and 250mg/ l . 
Suramin should not be c o n s i d e r e d a s first-line treatment 
for metastatic adrenocort ica l c a r c i n o m a . (3) To improve 
treatment options in adrenocort ica l carc inoma a s well a s 
for further investigation on the usefu lness of suramin, 
controlled prospect ive tr ials a r e urgently needed. 
Adrenocortical carcinoma (ACC) is a rare neoplasm with 
high malignancy. Because of its low incidence, well designed 
prospective therapeutic trials involving large numbers of 
patients are lacking. Thus treatment has not been 
standardized and the prognosis is usually poor. Most 
patients with metastatic disease are treated with mitotane, 
an adrenolytic drug, introduced into clinical use by 
Bergenstal et al. (1960). I t has never been proved that the 
use of mitotane in patients wi th A C C leads to significant 
prolongation of life and the drug is associated with 
significant side-effects (Luton et al, 1990). Since trials with 
cytotoxic chemotherapy or radiotherapy did not improve 
treatment results and even patients who responded 
experienced only transient palliative effects (Johnson & 
Greco, 1986; Percarpio & Knowlton, 1976), other treatment 
options for adrenocortical cancer are urgently needed. 
Suramin, a polysulphonated naphthylurea, has been used 
successfully in the treatment of African sleeping sickness 
since 1923. In 1986 its clinical use as an anti-HIV agent 
revealed remarkable adrenotoxicity leading to adreno-
cortical insufficiency (Levine et al, 1986; Kaplan et al., 
1987). In contrast, we recently found that lower doses of 
suramin in sleeping sickness improve the adrenocortical 
function which had been impaired by acute parasitic disease 
(Reincke et al, 1994). In animal experiments with Cynomol-
gus monkeys adrenocortical destruction with lymphocytic 
infiltration was seen after the administration of suramin 
(Feuillan et al, 1987). 
These findings led to the use o f suramin in the treatment 
of ACC. In recent studies, the therapeutic efficacy of 
suramin as a single agent was shown in patients with ACC 
(Stein et al., 1989; LaRocca et al., 1990a) and with prostatic 
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Table 1 Clinical data of patients (n = 9) prior to suramin therapy 
Survival after 
diagnosis onset of 
Patient Age Site of metastases 
no. Sex (years) disease Prior therapy (months) 
1 m 46 lung, liver s, rad(a), cyt(a), m 17 11 
2 f 32 lung, lc s 2 2 
3 f 57 lc, liver, node s 6 1 
4 m 52 lung, lc s, ag, m 20 6 
5 m 34 lung, liver, lc s, m, cyt(b), rad(b) 15 15 
6 f 53 liver, node, lc s, ag, m 4 4 
7 f 64 node, lc s, m 16 2 
8 f 47 lung s, ag, m 6 6 
9 m 63 bone s, m 70 2 
Site of disease (in order of occurrence): lc, local recurrence. 
Prior therapy (in chronological order): s, surgery; m, mitotane; ag, aminoglutethimide, rad, radiotherapy; rad(a), 40 Gy to tumour bed (post-
operative); rad(b), 10 Gy for local recurrence; cyt, cytostatic polychemotherapy; cyt(a), cisplatin + etoposide + bleomycin (2 cycles); cyt(b), 
vindesin + ifosfamide (5) and cisplatin + etoposide (3). 
carcinoma (LaRocca et al., 1991; Myers et al., 1992). In this 
paper we report the results of suramin treatment in nine 
patients with metastatic ACC treated between 1987 and 1992. 
Patients and methods 
Patients 
Between July 1987 and September 1982 we collected data on 
9 patients (5 females, 4 males, mean age 50 years, range 32-
67 years) treated with suramin in four hospitals. Patient 
details are shown in Table 1. A l l patients suffered from 
histologically proven metastatic adrenocortical carcinoma. 
At the start of suramin therapy elevated steroid concentra-
tions were found in six patients, three of whom had clinical 
signs of steroid excess (Table 2). 
In all patients primary treatment consisted in tumour 
removal by unilateral adrenalectomy; one patient also 
underwent ipsilateral nephrectomy and post-operative 
tumour bed irradiation. Treatment after onset of metas-
tases included, in 7 of 9 patients, the use of mitotane with a 
median daily dose of 6 0 g (range 2-5-8-0g) and a median 
duration of therapy of 2 months (range 1-7 months). This 
led to significant toxicity in all cases (including nausea, 
vertigo, hallucinations, abnormal liver function tests, 
allergic skin reactions and leucopenia). Other treatments 
used were aminoglutethimide (n = 3), cytotoxic poly-
chemotherapy (n = 2) and local radiotherapy (n = 1). 
Irrespective of treatment, all patients experienced disease 
progression. 
A l l patients gave written informed consent to suramin 
therapy after the experimental nature of the treatment had 
been explained. A l l former treatment was stopped at least 4 
weeks before initiation of suramin therapy except in patient 
9 who received additional radiotherapy for bone metastases 
Table 2 Endocrine tumour activity at start of suramin therapy 
(« = 9) 
Patient Endocrine 
no. activity Pathologically elevated steroids 
1 (+) 
1 -
17a-hydroxyprogesterone 
z 
3 + Cortisol 
4 (+) 17a-hydroxyprogesterone, dehy-
droepiandrosterone sulphate, 
oestradiol 
5 + Cortisol, 17a-hydroxyprogester-
one, aldosterone, dehydro-
epiandrosterone sulphate, 
androstenedione, testosterone, 
oestradiol, progesterone 
6 + Cortisol, aldosterone, andro-
stenedione, testosterone 
7 (+) 
8 
9 
Cortisol 
Endocrine activity: -(-Biochemical and clinical evidence of steroid 
excess, (+) only biochemical evidence of steroid excess; - no sign of 
steroid excess. 
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during the first 4 weeks of his suramin regimen. Two of the 
nine patients (nos 2 and 3) were treated with suramin after 
surgery without having received additional therapy for 
metastases encouraged by very promising initial results in 
two patients in this series (Allolio et al., 1989a; Baldus et al., 
1990) and in the series of the N I H group (Stein, personal 
communication, 1987; Stein et al., 1989; LaRocca et al, 
1990a). Both patients were suffering from rapidly progressing 
disease. 
Before initiation of suramin therapy all patients were in a 
general state equivalent to a Karnofsky index of at least 50. 
A l l patients had normal coagulation parameters, platelet 
counts above 120 x 109/1 and sufficient renal and hepatic 
function as assessed by a creatinine clearance above 0-7 ml/s 
and a serum total bilirubin concentration below 25 /rniol/1. 
In patients 4-9 maximum motor conduction velocity 
measurements in upper and lower limbs showed values 
within the normal range. 
Treatment 
Suramin (Germanin, Bayer, FRG) was diluted in 0-9% 
saline solution and administered intravenously. 
On day 0 all patients received a test dose of 200 mg 
suramin in a bolus injection in order to minimize the risk of 
anaphylactic reactions. Five patients (nos 1-4, 9) received 
suramin by bolus injections according to a dose regimen 
similar to standard therapy in sleeping sickness patients 
(Hawking, 1978) but achieving a higher cumulative dose 
during a shorter period. As more data on the toxicity and on 
target serum concentrations of suramin became available 
(Stein et al, 1989), the schedule was changed and in patients 
5-8 suramin was given by continuous infusion (0-35 g/m 2 
body surface/day during 10-16 days) aiming at suramin 
serum levels around 200mg/l. After the initial course 
treatment was interrupted for 14 days in all patients 
and maintenance doses were then given in weekly to 
two-weekly intervals depending on serum suramin 
concentrations. 
Baseline and follow-up studies 
Al l patients were evaluated prior to therapy and thereafter 
at regular intervals (4-8 weeks) by chest X-ray, abdominal 
sonography, and chest and abdominal computed tomo-
graphy. Additionally they underwent serial ophthalmological 
examinations including slit lamp studies. In patients 4-9 
monthly measurements of maximum motor conduction 
velocity in upper and lower limbs were performed. Weekly 
laboratory studies included blood cell counts, coagulation 
tests (partial thromboplastin time, prothrombin time (given 
as Quick value) and thrombin time) as well as renal and 
hepatic function parameters. 
Serum suramin concentration 
Serum suramin levels were determined by high-performance 
liquid chromatography (HPLC) using the method reported 
by Klecker and Collins (1985) with minor modifications. 
Measurements were carried out at least twice weekly during 
the treatment. 
Response criteria 
A tumour response to suramin was defined as complete 
(complete response, CR) i f there was no sign of measurable 
disease for at least 6 months. Partial response (PR) was 
equivalent to a more than 25% decrease, and progressive 
disease (POD) to a more than 25% increase of the 
radiologically measurable extent of disease. Stable disease 
(SD) was defined as < 25% increase or decrease of 
measurable disease. 
Statistical analysis 
Linear and exponential regression analyses were used to 
determine the correlation between blood or coagulation 
parameters and suramin serum level or cumulative dose. A 
correlation was considered statistically significant with a P 
value less than 005. 
Resu l ts 
During treatment periods varying from 1 to 15 months 
cumulative doses o f suramin ranging from 8-2 to 30-2 g were 
administered (see Table 3). 
Efficacy 
Three patients achieved a partial response (PR) during 
suramin therapy. Almost complete disappearance of multi-
ple lung metastases was observed for 5 months in patient 1 
and for 7 months in patient 8. In the third patient an 
extensive vertebral bone lesion (maximum diameter 8 cm) 
decreased in size by more than 50%. This patient also 
received local radiotherapy during the first 4 weeks of 
suramin treatment. There may have been an additive effect 
but regression of the lesion only became apparent 3 months 
after cessation of radiation therapy suggesting that the 
tumour regression was induced largely by continuous 
suramin therapy. Two of the nine patients showed transient 
disease stabilization (SD) during suramin treatment and 
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Table 3 Suramin therapy and tumour response (n — 9) 
Suramin therapy 
max. serum levels 
Survival 
after start 
serum continuously cumulative duration of suramin 
Pat. Tumour level ^200g/ml dose of therapy therapy 
no. response (mg/1) for ^ 4 weeks (g) (months) (months) 
1 PR(5) 476 + 24-7 7 8 
8 PR(7) 361 + 30-2 15 > 36 
9 PR(5) 232 + 18-2 8 9 
4 SD(3) 283 + 261 5 12 
6 SD(1) 246 - 116 1 2 
7 POD 199 - 100 1 2 
2 POD 169 - 11-5 2 3 
5 POD 93 - 12-3 1 1 
3 POD 64 — 8-2 1 1 
Tumour response: PR, partial response; SD, stable disease; POD, progressive disease (definitions see 'Response criteria')- Duration of response 
(months) is given in parentheses. 
was paralleled by a decline in elevated 17a-OH-progesterone 
levels, returning to elevated levels after relapse. In none of 
the five other patients with steroid-secreting tumours was an 
influence of suramin on steroid production detected. 
Treatment was terminated in two patients (1 PR, 1 SD) 
because of major toxicity (see below), in three patients 
because of relapse after initial tumour response (2 PR, 1 SD) 
and in four patients because of lack of response to suramin 
treatment. Relapse occurred in two of the three patients with 
PR after a period of at least 4 weeks with serum suramin 
levels continuously below 100 mg/1. In both cases reinduction 
therapy leading to serum concentrations above 200 mg/1 was 
without effect on tumour progression. Two patients (nos 4 
and 8) with initial response to suramin received additional 
cytotoxic polychemotherapy after they had relapsed. 
However, no tumour regression was found. The survival 
after initiation of suramin therapy varied between 1 and 
more than 36 months (median 9 months); patient 8 is still 
alive despite progressive disease. 
Toxicity (see Table 4) 
Renal and hepatic function impairment was only mild and 
transient: elevation of serum alkaline phosphatase (4/9) and 
albuminuria (2/9) were reversible during ongoing treatment. 
Elevation of serum creatinine (177^mol/l) was seen in the 
patient with unilateral nephrectomy (patient 1) and was 
reversible after cessation of treatment. 
A coagulopathy with a prolongation of partial thrombo-
plastin time (PTT) and an alteration of prothrombin time 
four of nine presented with progressive disease (POD) in 
spite of suramin therapy. PR or SD was associated with 
serum suramin levels ^ 200 mg/1 whereas in the four patients 
with POD serum levels ^ 200 mg/1 were measured only on 
single occasions (1/4) or never (3/4) (see Fig. 1). In all three 
cases with PR tumour regression was observed after a 
minimum of 4 weeks with serum suramin levels ranging 
continuously between 180 and 250 mg/1. 
In patient 1 (additionally suffering from 21-hydroxylase 
deficiency) radiologically visible shrinkage of tumour mass 
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Fig. 1 Maximum serum suramin concentration and tumour 
response during suramin therapy in nine patients with metastatic 
ACC. PR, SD, POD: see 'Response criteria'. , Target 
concentration. 
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Table 4 Toxicity during suramin therapy (« = 9) and association 
with mode of administration, serum concentration or cumulative 
dose of suramin 
Toxicity n Association 
Renal function impairment 
albuminuria 2 
(> 0-2g/day) 
creatinine elevation 1 
(> 133/xmol/l) 
Hepatic dysfunction 
alkaline phosphatase 
elevation (> 200 U/l) 4 
Coagulopathy 6 serum level 
Myelotoxicity 
thrombocytopenia 6 cumulative dose 
(< 120 x 109/1) 
haemoglobin decrease 2 cumulative dose? 
(> 30g/l) 
Neurological disorders 
paraesthesia and/or 
dysgeusia 3 bolus injection 
polyneuropathy 2 
including 
sensorimotor 
Guillain-Barre-like 
syndrome 1 serum level 
motor polyneuropathy 1 cumulative dose? 
Skin reactions 
generalized exanthema 3 bolus injection (n = 2) 
toxic epidermal 
necroeysis 1 
Vortex keratopathy 3 cumulative dose? 
(given as Quick value) was found in six of nine patients. Its 
incidence was positively correlated to suramin serum levels 
(PTT: r = 0-61, P < 0 0 1 ; Quick: r = 0 75, P < 001) (see 
Fig. 2a and b). 
Additionally, six patients presented with thrombocyto-
penia after doses of 8-2-11 -6 g suramin while three patients 
received similar doses without developing thrombocyto-
penia. However, this side-effect was significantly correlated 
with the cumulative dose of suramin (r = 0-69, P < 0 0 1 ; see 
Fig. 3). The coincidence of coagulopathy and thrombocy-
topenia did not result in bleeding complications. In two 
patients who underwent cytotoxic polychemotherapy prior 
to suramin a haemoglobin decrease was found after doses of 
20-6 and 21-7 g, respectively. 
Neurological impairment was noted in five patients. 
Three presented with paraesthesia and/or dysgeusia shortly 
after bolus injection reversible within minutes to hours. 
Patient 1 developed a severe Guillain-Barre-like sensorimotor 
polyneuropathy (PNP) following a period with serum 
suramin levels between 340 and 470mg/l. While motor 
function gradually improved the patient experienced sudden 
death by acute cardiac failure. Whether autonomic 
polyneuropathy or progressive disease was involved 
remains uncertain. In patient 4 a clinically silent motor 
PNP was detected after a total dose of 19-6 g suramin with 
serum levels ranging between 120 and 230mg/l. After 
cessation of therapy PNP did not improve during a 
follow-up period of 7 months. 
Skin reactions were seen in four patients, two patients 
showing a generalized rash shortly after bolus injection of 
suramin reversible within hours. Patient 8 presented with 
generalized exanthema independent of bolus injection 
reversible after the administration of steroids and transient 
interruption of suramin therapy. A n additional patient (no. 
6) died after 6 weeks of treatment after the sudden 
development o f toxic epidermal necrolysis while suramin 
( o ) 
2 0 -
10 L 
< i 1 1 1 i 
100 2 0 0 3 0 0 4 0 0 5 0 0 
Serum suramin concentration ( m g / l ) 
Fig. 2 Correlation between a, Quick value and b, partial 
thromboplastin time (PTT) respectively, and serum suramin 
concentration (ssc) (n = 9). Quick vs ssc: r = 0-75, P < 0-01; PTT 
vsssc: r = 0-61, P < 001. 
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Fig. 3 Correlation between platelet count (pc) and cumulative 
dose (cd) of suramin (n - 9). pc vs cd: r - 0-69, P < 001. 
concentrations ranged from 170 to 246 mg/1 (May & Allolio, 
1991). 
Vortex keratopathy was observed as a minor complaint in 
the three patients with the longest duration of therapy, 
occurring after a minimum of 8 weeks of treatment. 
It progressed slowly during ongoing treatment and 
remained unchanged during follow-up after cessation of 
suramin. 
Discuss ion 
The response rate in our patients is similar to the findings of 
Stein et al. (1989) and LaRocca et al. (1990a) in patients with 
ACC. In our series we observed a dramatic regression of 
disseminated lung metastases in two patients and a 
reduction of extensive bone metastases in one patient. The 
tumour response was related to serum suramin concentra-
tions ^ 200 mg/1 (target concentration). In our patients PR 
occurred only after 4 weeks with serum suramin levels near 
the target concentration. This is supported by in-vitro 
results in two adrenocortical carcinoma cell lines NCI-H295 
and SW13 showing cytotoxic effects of suramin only at 
concentrations above 200 mg/1 (Allolio et al., 1989b; 
LaRocca et al, 1990a). 
Unfortunately, in accordance with the results of LaRocca 
et al. (1990a) the partial responses were transient. I n our 
patients a relapse was seen 4-6 weeks after suramin levels 
declined below 100 mg/1. Reinduction therapy with suramin 
concentrations above 200 mg/1 resulted in a high incidence 
of side-effects without tumour response. This escape 
phenomenon remains to be explained. 
Stein et al. (1989) reported that in patients with high 
tumour bulk it took far higher doses to reach the target 
serum concentrations and they suggested an accumulation 
of suramin in tumour tissue. Four of our nine patients 
suffered from extensive metastases ( ^ 3 sites of disease) and 
target concentrations were achieved in none of these. A l l 
experienced progressive disease. 
Initially the adrenotoxic properties of suramin (Feuillan 
et al., 1987) provided the rationale for the use of this drug in 
adrenal cancer. However, there is increasing evidence that 
suramin interferes with a variety of regulatory processes 
involved in malignant cell transformation and growth. 
Because of its polyanionic molecular structure suramin 
binds to positively charged proteins and may lead to 
disturbances of cellular energy balance by inhibition of 
ATPase (Fortes et al., 1973) or LDL-receptor binding 
(Schneider et al, 1982). Suramin is known also to influence 
cell replication by inhibition of RNA- and D N A -
polymerases (Basu & Modak, 1985; Jindal et al., 1990). 
Furthermore, the suramin molecule shows structural 
similarities to sulphated glycosaminoglycans (GAGs) 
which are ubiquitous on cell surfaces and in matrix tissue 
and take part in cell contact, recognition and growth control 
(Dietrich & Montes de Oca, 1978). Some GAG-degrading 
enzymes produced by tumour cells facilitating invasion and 
metastases are inhibited by suramin (Nakajima et al., 1991). 
This also leads to G A G accumulation in serum and tissue 
(Constantopoulos et al., 1980). 
The most likely explanation for the anti-tumour activity 
of suramin may be its interaction with growth factors (GFs) 
which are able to promote tumour growth by autocrine or 
paracrine stimulation. Direct binding of the suramin 
molecule to GFs and/or to their receptors has been 
described for platelet-derived growth factor (PDGF) 
(Williams et al., 1984; Hosang, 1985), epidermal growth 
factor (EGF) (Betsholtz et al., 1986), transforming growth 
factor beta (TGF-/3) (Coffey et al., 1987) as well as for GFs 
with angiogenic capacity (AFs) (Vaisman et al., 1990; Sato 
& Rifkin, 1988). An important role for EGF and bFGF and 
for AFs in promoting malignant growth has been suggested 
for adrenocortical carcinoma by in-vitro studies (Kamio et 
al., 1990, 1991; Wellstein et al., 1990; Plouet & Moukadiri , 
1990). 
In accord with its multitude of possible anti-tumour 
actions suramin also leads to a variety of side-effects. In our 
patients alterations of renal and hepatic function parameters 
were only mild and seemed to be associated with the loading 
period and/or bolus injection. The incidence of renal 
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dysfunction noted by Stein et al. (1989) was far higher (10/ 
10) than in our patients (2/9); this may be explained by the 
fact that all patients presented by Stein et al. had undergone 
unilateral nephrectomy (in our patients only 1/9). Other 
mild side-effects possibly related to transient peaks of 
suramin concentration after bolus injection were generalized 
rash (2/9) and paraesthesiae (3/9). 
A serious toxicity positively correlated with suramin 
serum concentration was coagulopathy seen in six of our 
nine patients. Similar to Hörne et al. (1988) significant 
changes of clotting parameters became measurable at 
suramin serum levels around 250mg/l. We found an 
involvement of both intrinsic and extrinsic clotting 
systems. Home et al. (1988) studied plasma from suramin 
treated patients and found an accumulation of the GAGs 
heparan sulphate and dermatan sulphate exhibiting a 
heparin-like anticoagulant activity. In a recent study 
Hörne et al. (1992) found direct inhibitory effects of 
suramin on procoagulant proteins (factors X I I , X I , V I I I , 
X , V) explaining the involvement of the intrinsic clotting 
system. Such direct effects have already been described by 
Eisen and Loveday (1973) who also found an anti-thrombin 
activity of suramin. In contrast to the patients reported by 
Stein et al. (1989) no significant bleeding complications were 
observed in our patients. A correlation between tumour 
response and incidence of suramin-induced coagulopathy 
(Stein et al., 1989) was also not seen in our patients. Another 
toxicity associated with G A G accumulation was vortex 
keratopathy. I t resulted in minor complaints but may bear 
the risk of visual function impairment as histological 
examination of lens epithelia and retinal cells from suramin 
treated patients revealed significant G A G accumulation 
(Holland et al., 1988). In our patients keratopathy seemed to 
be related to the cumulative dose of suramin. 
The incidence of myelotoxicity during suramin treatment 
also seemed to depend on cumulative dose. A specific 
accumulation of suramin in bone marrow cells has been 
described repeatedly and may lead to direct interference of 
the drug with haemopoietic growth factors as is known for 
heparan sulphate (Buys et al, 1978; Constantopoulos et al, 
1980; Roberts et al, 1980; Roberts et al, 1988). This 
suggests that suramin induced myelotoxicity will be 
reversible paralleling tissue clearance. Suramin related 
thrombocytopenia may also be caused by complement 
activation following the formation of drug-antibody 
complexes; a case of severe immune mediated thrombo-
cytopenia has been reported recently by Seidman et al. 
(1993). 
Another possibly immune mediated toxicity is Guillain-
Barre-like Polyneuropathie syndrome (GBS) which devel-
oped in one of our patients while serum suramin 
concentrations varied between 300 and 400mg/l. LaRocca 
et al. (1990b) found a 40% risk of GBS in patients with 
serum concentrations above 350mg/l and noted a good 
response to plasmapheresis. In one additional patient we 
observed a clinically silent motor polyneuropathy slowly 
progressing with increasing cumulative dose of suramin, an 
association that has not been described yet. 
A n immunosuppressive influence of the drug was 
proposed by O'Donnell et al. (1992) who described two 
patients who developed keratoacanthoma during suramin 
therapy. As a possible mechanism for immunosuppression 
Mills et al. (1990) described an inhibitory effect of suramin 
on the interleukin-2 binding to lymphoid cells possibly 
leading to altered proliferation and differentiation. 
In our series allergic skin reactions were frequent (4/9) 
and may be serious, as one patient experienced a lethal toxic 
epidermal necrolysis (May & Allolio, 1991). A history of 
drug-induced allergic skin reactions was reported by three of 
the four symptomatic patients and perhaps should be 
considered an exclusion criterion for suramin treatment. 
In a recent letter Falkson and Rapoport (1992) suggested 
the administration of 200 mg hydrocortisone preceding each 
suramin injection and reported promising reduction of 
allergic skin reactions. As Wilks et al. (1991) demonstrated 
in vitro, combination treatment with steroids and suramin 
may also support the anti-tumour efficacy by increased 
inhibition of angiogenesis. 
The incidence of serious side-effects (polyneuropathy and 
coagulopathy) associated with serum suramin concentra-
tions above 300mg/l and the anti-tumour activity of 
suramin being found to depend on serum concentrations 
above 200 mg/1, demonstrate a narrow therapeutic window. 
This suggests mandatory strict serum level monitoring 
during suramin therapy. 
Suramin treatment is hampered by the unique pharma-
cokinetic characteristics of the drug: an extremely strong 
protein binding (99-7%), an extensive lysosomotropic tissue 
accumulation (>90%), and a lack of metabolism leading to 
a slow renal clearance and a plasma half-life of 44-54 days 
(Buys et al, 1978; Collins et al, 1986). Recent studies 
suggested a computer-assisted Bayesian approach for 
development of individualized dosing schemes (Scher et 
al, 1992; Cooper et al, 1992; van Rijswijk et al, 1992). 
The use of suramin in combination therapies may lead to 
a dose reduction and thereby to a reduction of toxicity and/ 
or an enhancement of anti-tumour efficacy. Vierhapper et al. 
(1989) reported on a patient with ACC presenting with 
partial response during combined treatment with suramin 
and mitotane. Furthermore, there are in-vitro data suggest-
ing synergistic activities of suramin with cytotoxic drugs like 
cyclophosphamide (Osswald & Youssef, 1979) and tumour 
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necrosis factor alpha (Fruehauf et al., 1990). Another 
possibility for avoiding toxicity may be the use of structural 
analogues of suramin (Baghdiguian et al., 1990; 1991). 
In conclusion, suramin is of limited efficacy in patients 
with metastatic adrenocortical carcinoma and its use is 
complicated by a high incidence of serious toxicity. The 
unique properties of suramin demand further research. A t 
the moment it is not a first-line treatment for metastatic 
adrenocortical carcinoma. Controlled prospective trials are 
urgently needed to improve the treatment options for this 
malignancy. 
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